Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Codivir in ART-naïve HIV
NCT06676410Phase 2Recruiting
- Sponsor
- Code Pharma
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Codivir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Code Pharma. Primary endpoints: Estimated viral reservoir size by total blood proviral DNA at 12 weeks and CD4+ blood count at 12 weeks. Started Jul 2023; status: recruiting.
02
Drugs
Codivir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06676410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676410.